BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, April 25, 2025
See today's BioWorld Asia
See today's BioWorld
Home
» South Korea’s Genexine begins phase I/IIa trials for COVID-19 vaccine
To read the full article
sign up for free
or
sign in
.
South Korea’s Genexine begins phase I/IIa trials for COVID-19 vaccine
June 23, 2020
By
David Ho
and
Gina Lee
HONG KONG – South Korea-based Genexine Inc. has started enrolling a phase I/II trial for a DNA vaccine targeting COVID-19 called GX-19.
BioWorld
BioWorld Asia
Clinical
Coronavirus
Vaccine
Asia-Pacific
